XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Location: United States
Employees: 201-500
Total raised: $20M
Founded date: 1999
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 20.11.2012 | - | $20M | - | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 07.06.2012 | GSK gets FDA approval on Horizant to treat post-shingles pai... | The first commercial sales of Horizant for PHN will trigger a $10 million milestone payment to XenoP... | medcitynew... |
| 24.02.2012 | GSK sues partner XenoPort over marketing allegations on RLS ... | GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, entered a partnershi... | medcitynew... |
| - | GSK sues partner XenoPort over marketing allegations on RLS ... | GlaxoSmithKline (NYSE:GSK) is pushing back against drug partner XenoPort (NASDAQ:XNPT) over claims t... | medcitynew... |
| - | GSK gets FDA approval on Horizant to treat post-shingles pai... | GlaxoSmithKline‘s (NYSE:GSK) restless leg syndrome drug Horizant has received U.S. approval for the ... | medcitynew... |